Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn`s Disease

Study:

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Intravenous Antegren(TM) (Natalizumab) in Subjects With Moderately to Severely Active Crohn`s Disease With Elevated C-Reactive Protein

Rationale:

n/a

Purpose:

The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn`s Disease.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Crohn`s Disease Drug: Antegren(TM) (natalizumab) Phase 3

Verified by Elan Pharmaceuticals March, 2012

Sponsored by: Elan Pharmaceuticals
Information provided by: Elan Pharmaceuticals
ClinicalTrials.gov identifier: NCT00078611

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.